Therapeutic potential of bone marrow-derived mesenchymal stem cells and imatinib in a rat model of liver fibrosis.

[1]  E. Kardami,et al.  Simvastatin increases temozolomide‐induced cell death by targeting the fusion of autophagosomes and lysosomes , 2020, The FEBS journal.

[2]  E. Samiei,et al.  Mechanisms of simvastatin myotoxicity: The role of autophagy flux inhibition. , 2019, European journal of pharmacology.

[3]  M. Aller,et al.  Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials , 2019, Stem cells international.

[4]  E. Zuba-Surma,et al.  Challenges and Controversies in Human Mesenchymal Stem Cell Therapy , 2019, Stem cells international.

[5]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[6]  A. El-Serafi,et al.  Therapeutic potential of human umbilical cord derived mesenchymal stem cells on rat model of liver fibrosis. , 2019, American journal of stem cells.

[7]  G. Solgi,et al.  Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl4)-induced liver fibrosis in rats , 2018, Drug and chemical toxicology.

[8]  D. Sabry,et al.  Treatment Efficiency of Different Routes of Bone Marrow-Derived Mesenchymal Stem Cell Injection in Rat Liver Fibrosis Model , 2018, Cellular Physiology and Biochemistry.

[9]  G. Pera,et al.  High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population‐Based Study , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  C. Shao,et al.  Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases , 2018, Nature Reviews Nephrology.

[11]  S. Ghavami,et al.  Autophagy modulates transforming growth factor beta 1 induced epithelial to mesenchymal transition in non-small cell lung cancer cells. , 2018, Biochimica et biophysica acta. Molecular cell research.

[12]  T. Luedde,et al.  Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis , 2018, Hepatology.

[13]  P. Marcellin,et al.  Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[14]  Johan Lennartsson,et al.  The PDGF/PDGFR pathway as a drug target. , 2017, Molecular aspects of medicine.

[15]  S. Hashemi,et al.  Development of experimental fibrotic liver diseases animal model by Carbon Tetracholoride , 2017, Gastroenterology and hepatology from bed to bench.

[16]  T. Shalaby,et al.  Hepatic stellate cell‐targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[17]  M. Zali,et al.  Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow , 2017, Gastroenterology and hepatology from bed to bench.

[18]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[19]  D. Zhang.  A clinical study of bone mesenchymal stem cells for the treatment of hepatic fibrosis induced by hepatolenticular degeneration. , 2017, Genetics and molecular research : GMR.

[20]  T. Ochiya,et al.  Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell , 2017, Regenerative therapy.

[21]  H. Akbari Javar,et al.  Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes , 2017, Drug design, development and therapy.

[22]  G. Hirschfield,et al.  Mesenchymal stromal cells and liver fibrosis: a complicated relationship , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  R. Weiskirchen,et al.  The PDGF system and its antagonists in liver fibrosis. , 2016, Cytokine & growth factor reviews.

[24]  Ting Lin,et al.  New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials , 2016, Front. Pharmacol..

[25]  K. Poelstra.  Liver fibrosis in 2015: Crucial steps towards an effective treatment , 2016, Nature Reviews Gastroenterology &Hepatology.

[26]  A. Rastogi,et al.  Molecular and Cellular Functions Distinguish Superior Therapeutic Efficiency of Bone Marrow CD45 Cells Over Mesenchymal Stem Cells in Liver Cirrhosis , 2016, Stem cells.

[27]  S. Alavian,et al.  Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. , 2015, World journal of gastroenterology.

[28]  K. McGlynn,et al.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. , 2015, Clinics in liver disease.

[29]  R. Schwabe,et al.  Hepatic inflammation and fibrosis: Functional links and key pathways , 2015, Hepatology.

[30]  R. Bruno,et al.  Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[31]  I. Dixon,et al.  Autophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts , 2015, Cell Death and Disease.

[32]  P. Morel,et al.  Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. , 2015, Journal of hepatology.

[33]  Qiyu Zhang,et al.  Adipose-derived mesenchymal stem cells inhibit activation of hepatic stellate cells in vitro and ameliorate rat liver fibrosis in vivo. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[34]  Dongliang Li,et al.  Therapeutic effect comparison of hepatocyte-like cells and bone marrow mesenchymal stem cells in acute liver failure of rats. , 2015, International journal of clinical and experimental pathology.

[35]  G. Shiha,et al.  Tracking anti‐fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight , 2014, Clinical and experimental pharmacology & physiology.

[36]  J. Rakela,et al.  Cellular therapy for liver disease. , 2014, Mayo Clinic proceedings.

[37]  T. Sacha,et al.  Imatinib in Chronic Myeloid Leukemia: an Overview , 2013, Mediterranean journal of hematology and infectious diseases.

[38]  M. S. Farhan,et al.  Short‐term evaluation of autologous transplantation of bone marrow–derived mesenchymal stem cells in patients with cirrhosis: Egyptian study , 2013, Clinical transplantation.

[39]  N. Buus,et al.  Antifibrotic effect after low‐dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open‐label non‐randomized, uncontrolled clinical trial , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[40]  C. Gialeli,et al.  Imatinib as a key inhibitor of the platelet‐derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells , 2013, The FEBS journal.

[41]  G. Gurtner,et al.  Stem cell recruitment after injury: lessons for regenerative medicine. , 2012, Regenerative medicine.

[42]  N. Aghdami,et al.  Effect of Mesenchymal Stem Cells on Doxorubicin-Induced Fibrosis , 2012, Cell journal.

[43]  M. Chilosi,et al.  Comparison of Epithelial Differentiation and Immune Regulatory Properties of Mesenchymal Stromal Cells Derived from Human Lung and Bone Marrow , 2012, PloS one.

[44]  G. Kazemier,et al.  Secreted factors of human liver-derived mesenchymal stem cells promote liver regeneration early after partial hepatectomy. , 2012, Stem cells and development.

[45]  K. Coombs,et al.  Virus‐triggered autophagy in viral hepatitis – possible novel strategies for drug development , 2011, Journal of viral hepatitis.

[46]  Mohamed Hegazy,et al.  Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells , 2011, European journal of gastroenterology & hepatology.

[47]  D. Ratner,et al.  Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[48]  A. Gabrielli,et al.  Imatinib for refractory chronic graft-versus-host disease with fibrotic features. , 2009, Blood.

[49]  N. Hayashi,et al.  Transplantation of basic fibroblast growth factor-pretreated adipose tissue-derived stromal cells enhances regression of liver fibrosis in mice. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[50]  O. Distler,et al.  Imatinib as a novel therapeutic approach for fibrotic disorders. , 2008, Rheumatology.

[51]  L. Dai,et al.  The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. , 2009, Stem cell research.

[52]  Oliver Distler,et al.  Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. , 2009, Arthritis and rheumatism.

[53]  O. Distler,et al.  Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. , 2008, Rheumatology.

[54]  G. Enns,et al.  Cell-based therapies for metabolic liver disease. , 2008, Molecular genetics and metabolism.

[55]  P. Bianco,et al.  Mesenchymal stem cells: revisiting history, concepts, and assays. , 2008, Cell stem cell.

[56]  M. Najimi,et al.  Stem cells for liver tissue repair: current knowledge and perspectives. , 2008, World journal of gastroenterology.

[57]  D. Sabry,et al.  Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. , 2007, Clinical biochemistry.

[58]  E. Roeb,et al.  Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. , 2007, Journal of hepatology.

[59]  D. Blumenthal,et al.  Differential effects of imatinib on PDGF‐induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells , 2006, Journal of cellular biochemistry.

[60]  H. Ohgushi,et al.  Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. , 2006, Journal of hepatology.

[61]  H. Tilg,et al.  The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Yu-hao Liu,et al.  [Flk1+ mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice]. , 2005, Sheng wu gong cheng xue bao = Chinese journal of biotechnology.

[63]  Tsutomu Masaki,et al.  Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[64]  H. Nishina,et al.  Transplantation of bone marrow cells reduces CCl4‐induced liver fibrosis in mice , 2004, Hepatology.

[65]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[66]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[67]  R. Tuan,et al.  Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy , 2004, Journal of cellular and molecular medicine.

[68]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[69]  S. Dooley,et al.  Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[70]  D Chappard,et al.  Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. , 1998, Journal of hepatology.